Drugs / UCARTCS1A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04142619 | Nov 2019 → Jun 2023 | refractory plasma cell neoplasm | Cellectis S.A. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-07-06 | Cellectis S.A. | Regulatory Cellectis Reports Clinical Hold Placed on MELANI-01 Study cellectis.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-07-06 | Cellectis S.A. | Cellectis Reports Clinical Hold Placed on MELANI-01 Study cellectis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCARTCS1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04142619 ↗ |
| Modality | Cell therapy | “Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor” NCT04142619 ↗ |